Binghe Xu Selected Research

pamiparib

2/2023	Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
1/2021	Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Binghe Xu Research Topics

Disease

194	Breast Neoplasms (Breast Cancer) 03/2024 - 11/2007
83	Neoplasms (Cancer) 04/2024 - 05/2008
51	Triple Negative Breast Neoplasms 02/2024 - 01/2013
22	Disease Progression 12/2023 - 11/2007
21	Neutropenia 05/2023 - 11/2007
19	Neoplasm Metastasis (Metastasis) 01/2023 - 08/2012
7	Leukopenia 12/2023 - 05/2015
7	Diarrhea 03/2021 - 06/2013
6	Peripheral Nervous System Diseases (PNS Diseases) 02/2023 - 01/2017
6	Lymphatic Metastasis 01/2021 - 10/2010
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 10/2009
6	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2014 - 11/2002
5	Hand-Foot Syndrome 03/2021 - 10/2019
5	Stomach Neoplasms (Stomach Cancer) 01/2017 - 03/2015
5	Lung Neoplasms (Lung Cancer) 01/2014 - 05/2008
4	Pneumonia (Pneumonitis) 01/2023 - 01/2018
4	Febrile Neutropenia 11/2022 - 05/2014
4	Carcinogenesis 05/2021 - 05/2008
4	Exanthema (Rash) 12/2020 - 09/2014
4	Nausea 10/2019 - 09/2017
3	Thrombocytopenia (Thrombopenia) 05/2023 - 07/2021
3	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2023 - 01/2022
3	Cardiotoxicity 01/2022 - 12/2014
3	Stomatitis 01/2022 - 05/2014
3	Hypertension (High Blood Pressure) 03/2021 - 05/2015
3	Cardiovascular Diseases (Cardiovascular Disease) 03/2021 - 12/2018
3	Circulating Neoplastic Cells 01/2021 - 10/2016
3	Esophageal Neoplasms (Esophageal Cancer) 01/2019 - 03/2015
3	Pathologic Complete Response 01/2019 - 04/2016
3	Fatigue 01/2018 - 11/2007
2	Prostatic Neoplasms (Prostate Cancer) 01/2024 - 06/2023

Drug/Important Bio-Agent (IBA)

46	Hormones (Hormone)IBA 03/2024 - 01/2011
37	Trastuzumab (Herceptin)FDA Link 10/2023 - 01/2013
33	human ERBB2 proteinIBA 03/2024 - 09/2012
31	AnthracyclinesIBA 01/2022 - 11/2007
28	Capecitabine (Xeloda)FDA Link 12/2023 - 11/2007
25	Paclitaxel (Taxol)FDA LinkGeneric 01/2024 - 12/2010
23	ErbB Receptors (EGF Receptor)IBA 02/2024 - 06/2013
22	taxaneIBA 02/2023 - 11/2007
19	Biomarkers (Surrogate Marker)IBA 11/2023 - 05/2008
19	Taxoids (Taxanes)IBA 02/2023 - 11/2007
16	PlatinumIBA 01/2023 - 05/2008
13	pyrotinibIBA 12/2023 - 09/2017
13	Vinorelbine (Navelbine)FDA LinkGeneric 01/2023 - 01/2010
13	Epirubicin (Ellence)FDA LinkGeneric 01/2023 - 09/2012
12	Docetaxel (Taxotere)FDA Link 10/2023 - 05/2014
12	Estrogen ReceptorsIBA 12/2022 - 01/2013
12	Lapatinib (GW572016)FDA Link 01/2021 - 01/2013
11	Progesterone Receptors (Progesterone Receptor)IBA 10/2022 - 01/2013
10	Aromatase InhibitorsIBA 03/2024 - 01/2011
10	Phenobarbital (Luminal)FDA Link 02/2022 - 12/2013
9	Fulvestrant (Faslodex)FDA Link 08/2023 - 01/2011
9	Indicators and Reagents (Reagents)IBA 02/2023 - 10/2016
9	Proteins (Proteins, Gene)FDA Link 01/2023 - 10/2008
8	Carboplatin (JM8)FDA LinkGeneric 01/2024 - 07/2011
8	Circulating Tumor DNAIBA 11/2023 - 01/2017
7	Letrozole (Femara)FDA LinkGeneric 03/2024 - 01/2011
7	exemestane (Aromasin)FDA Link 08/2023 - 04/2014
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2023 - 09/2012
6	Tyrosine Kinase InhibitorsIBA 02/2024 - 04/2014
6	Everolimus FDA Link 12/2023 - 05/2014
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2008
6	ixabepilone (BMS 247550)FDA Link 08/2012 - 11/2007
5	Phosphotransferases (Kinase)IBA 01/2024 - 05/2017
5	apatinibIBA 01/2024 - 10/2014
5	Immune Checkpoint InhibitorsIBA 11/2023 - 03/2016
5	pertuzumabIBA 02/2023 - 01/2019
5	olaparibIBA 01/2023 - 10/2017
5	Epidermal Growth Factor (EGF)IBA 01/2023 - 04/2016
5	camrelizumabIBA 02/2019 - 01/2018
4	Anastrozole (Arimidex)FDA LinkGeneric 03/2024 - 01/2011
4	TOR Serine-Threonine KinasesIBA 12/2023 - 05/2019
4	dalpiciclibIBA 01/2023 - 04/2021
4	Tamoxifen FDA LinkGeneric 12/2022 - 01/2018
4	Cyclin-Dependent Kinase 4IBA 11/2022 - 04/2021
4	MicroRNAs (MicroRNA)IBA 01/2018 - 08/2011
4	Cisplatin (Platino)FDA LinkGeneric 12/2015 - 10/2008
4	Gemcitabine FDA Link 12/2014 - 12/2010
3	130-nm albumin-bound paclitaxelIBA 02/2024 - 11/2022
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2023 - 11/2016
3	anlotinibIBA 11/2023 - 03/2021
3	Histone Deacetylase InhibitorsIBA 08/2023 - 01/2021
3	MTOR InhibitorsIBA 08/2023 - 12/2020
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 06/2023 - 01/2016
3	Ado-Trastuzumab EmtansineIBA 01/2023 - 07/2021
3	trastuzumab deruxtecanIBA 01/2023 - 01/2022
3	eribulin FDA Link 01/2023 - 01/2019
3	palbociclibIBA 11/2022 - 01/2021
3	neratinibIBA 10/2019 - 11/2014
2	ribociclibIBA 03/2024 - 01/2023
2	Cell-Free Nucleic AcidsIBA 03/2024 - 10/2020
2	Mechanistic Target of Rapamycin Complex 1IBA 12/2023 - 01/2021
2	Alanine Transaminase (SGPT)IBA 12/2023 - 11/2016

Therapy/Procedure

89	Therapeutics 04/2024 - 11/2002
75	Drug Therapy (Chemotherapy) 06/2023 - 05/2008
22	Neoadjuvant Therapy 01/2024 - 09/2012
17	Adjuvant Chemotherapy 02/2023 - 01/2015
8	Immunotherapy 11/2023 - 01/2019
6	Radiotherapy 01/2023 - 10/2010
3	Aftercare (After-Treatment) 01/2022 - 11/2014